GBA Presents: House of Gummy-!

[stonedinvestor]

Ya sure about this? It's been chopping all throughout 2023. I would feel more comfy taking a short position, now that it's trading near the upper channel.

View attachment 330585

I am quite positive on SMAR. Choppiness? Who cares. 2024 is for catch up plays-- I am looking fore EXACTLY these type of ideas 1> Hopefully AI ish 2> with a prior high within grasp or under the price. I will not be chasing any names.

This may look choppy but in fact Over the past quarter, shares of Smartsheet have risen 21.08%, and are up 28.67% in the last year. On the other hand, the S&P 500 has only moved 12.63% and 26.05%, respectively.

So we have recent out performance to a name that has been at this price level before! Now we ask what is in the future?

Over the past two months, 7 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost SMAR's consensus estimate, increasing from $0.54 to $0.69 in the past 60 days. Looking at the next fiscal year, 7 estimates have moved upwards while there have been no downward revisions in the same time period.

 

[stonedinvestor]

That is how you find ideas folks. Now lets look at Flutter my other large purchase.

They will be listing here before the super bowl<------- !!

Flutter Entertainment, which is based in Ireland, has reportedly secured its plans to list on the New York Stock Exchangeby Jan. 29, 2024, less than two weeks before Super Bowl LVIII. FanDuel is the market leader for online sports betting with 39.3% of the market share, according to an August report by Eilers and Krejcik Gaming.

 

[stonedinvestor]

TTOO…recently regained nasdaq compliance. Lots of volume coming in last week. Not sure what’s going on. They are a leader in the detection of sepsis-causing pathogens. Up 16% yesterday.

TY Mac for chipping in. I will look into TTOO today!

 

[stonedinvestor]

Stoney you mentioned CYTK over the past few years. The Jan 19, 2024 had almond 22,000 of the $100 calls trade. What attracted you to them previously?

TEd this was a $30-$44 sort of name that had take out chatter in Dec of 01' / Dealreporter published something. I'm sure that was when I was riding it. I'm not sure what set off this recent super spike it's impressive but I would do as management did just yesterday....

Director Wendall Wierenga Sells 10,000 Shares of Cytokinetics Inc (CYTK)
Fri, December 29, 2023 at 7:01 AM EST

 

[stonedinvestor]

Last day of the trading year news is very slow--

Constellation Brands risk/reward positive ahead of Q3, says Goldman Sachs » 19:26 STZ

I have stuck with this name. Stubborn. I get this way but the company itself has done nothing wrong.

 

[stonedinvestor]

ANNX-

THIS LOOKS INTERESTING:

- DEC 20 DID A OFFERING THAT WAS WELL RECEIVED
Annexon stock jumps on pricing of $125M public offering of common stock
SA NewsWed, Dec. 20

- HOW MANY TIMES HAVE YOU SEEN A BIO GO UP 30% ON OFFERING MORE SHARES?
INVESTORS WERE VERY HAPPY TO HAVE MORE CASH RAISED AT A GOOD LEVEL AS PERCEIVED BY THEM-

Annexon stock rallies 30% on drug updates, $125M offering pricing

THIS COULD RUN TO $6./
Company Profile

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company’s C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington’s disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.



TODAY-->Annexon director buys $1.0M in common stock » 16:44 ANNX

LAST GUMMY OF THE YEAR!!!


GUMMY->ANNXAnnexon, Inc.

$4.57-0.06(-1.30%)4:00 PM 12/28/23
NASDAQ |$USD |Pre-Market:$4.67+0.10(+2.19%)8:06

 

[stonedinvestor]

BLACK SWAN IN THE MAKING?

 

[stonedinvestor]

 

[stonedinvestor]

Putin very mad he lost 3-5 fancy jets over Christmas due to patriot missals <-- they work!

and Japan who manufacturers them to our standards and has a no export weapon mantra is sending a bunch to the US so we can turn them around to Ukraine!

Tricky!

 

[stonedinvestor]